
Insiders seem to have made the most of their holdings by selling HK$27m worth of Biosysen Limited (HKG:1355) stock at an average sell price of HK$0.12 during the past year. After the stock price dropped 42% last week, the company's market value declined by HK$465m, but insiders were able to mitigate their losses.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
The insider, Fuer Yuan, made the biggest insider sale in the last 12 months. That single transaction was for HK$6.3m worth of shares at a price of HK$0.13 each. So it's clear an insider wanted to take some cash off the table, even below the current price of HK$0.35. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 33% of Fuer Yuan's stake.
Biosysen insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
See our latest analysis for Biosysen
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
The last quarter saw substantial insider selling of Biosysen shares. In total, insider Baoshan Li dumped HK$2.8m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Biosysen insiders own about HK$256m worth of shares (which is 40% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
An insider hasn't bought Biosysen stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Be aware that Biosysen is showing 6 warning signs in our investment analysis, and 4 of those don't sit too well with us...
Of course Biosysen may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.